Yun Pyo Kang

Assistant Professor

Seoul National University
Country flagSouth Korea

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

During T-cell-mediated inflammatory responses, T cells are activated upon recognizing specific antigens presented by antigen-presenting cells. This recognition initiates signaling through the TCR and CD28, leading to their activation and subsequent clonal expansion. Within the signaling cascades triggered by TCR and CD28 engagement, the CD28-PI3K pathway serves as a central regulator of metabolic reprogramming in T cells, supporting the biosynthetic needs essential for their effective proliferation. In this study, we found that the regulation of PANK4 plays a role in TCR/CD28-mediated CD4 + T-cell proliferation by regulating de novo lipid synthesis. The CD28 signaling pathway negatively regulates PANK4 through direct binding with PDK1, thereby controlling de novo lipid synthesis for CD4 + T-cell proliferation. Interestingly, we found that Pank4 -deficient CD4 + T cells enhance coenzyme A synthesis and glutaminolysis, whereby glutamine contributes carbon for fatty acid synthesis and provides nitrogen for coenzyme A biosynthesis. The regulatory role of PANK4 in CD4 + T-cell proliferation was confirmed in models of experimental colitis and influenza A virus infection, where Pank4 -deficient CD4 + T cells exhibited greater expansion than their wild-type counterparts when co-transferred. Our findings suggest that PANK4 regulation of de novo lipid synthesis is crucial for TCR/CD28-induced CD4 + T-cell proliferation and represents a potential target for modulating general CD4 + T-cell responses.

Year:

2025

Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we examined patients’ intratumoral immune infiltrates and observed that elevated levels of immunoregulatory macrophages in pre-infusion tumor biopsies are correlated with poor clinical responses. CAR T cell-produced interferon-gamma (IFN-γ) promotes the expression of inducible nitric oxide synthase (iNOS, NOS2) in immunoregulatory macrophages, impairing CAR T cell function. Mechanistically, iNOS-expressing macrophages upregulated the p53 pathway, mediating apoptosis and cell cycle arrest in CAR T cells, while downregulating the MYC pathway involved in ribosome biogenesis and protein synthesis. Furthermore, CAR T cell metabolism is compromised by depletion of glycolytic intermediates and rewiring of the TCA cycle. Pharmacological inhibition of iNOS enhances the CAR T cell treatment efficacy in B cell tumor-bearing mice. Notably, elevated levels of iNOS+CD14+ monocytes were observed in leukaphereses of patients with non-durable response to CAR T cell therapy. These findings suggest that mitigating iNOS in tumor-associated macrophages (TAMs) by blocking IFN-γ secretion from CAR T cells will improve outcomes for LBCL patients.

Year:

2025

A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and inferior clinical responses in 146 patients with DLBCL treated with axicabtagene ciloleucel. We develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) and ferritin to classify patients into low-, intermediate-, and high-risk groups. We observe that patients in the high-risk category were more likely to develop grade ≥3 toxicities and had inferior overall and progression-free survival. We sought to validate our findings with two independent international cohorts demonstrating that patients classified as low-risk have excellent efficacy and safety outcomes. Based on routine and readily available laboratory tests that can be obtained prior to lymphodepleting chemotherapy, this simple risk stratification can inform patient selection for CAR T-cell therapy. Significance: CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes. This article is featured in Selected Articles from This Issue, p. 80

Year:

2024

A subset of patients with diffuse large B-cell lymphoma (DLBCL) treated with CD19 chimeric antigen receptor (CAR) T-cell therapy have poor clinical outcomes. We report serum proteins associated with severe immune-mediated toxicities and inferior clinical responses in 146 patients with DLBCL treated with axicabtagene ciloleucel. We develop a simple stratification based on pre-lymphodepletion C reactive protein (CRP) and ferritin to classify patients into low-, intermediate-, and high-risk groups. We observe that patients in the high-risk category were more likely to develop grade ≥3 toxicities and had inferior overall and progression-free survival. We sought to validate our findings with two independent international cohorts demonstrating that patients classified as low-risk have excellent efficacy and safety outcomes. Based on routine and readily available laboratory tests that can be obtained prior to lymphodepleting chemotherapy, this simple risk stratification can inform patient selection for CAR T-cell therapy. Significance: CAR T-cell therapy has changed the treatment paradigm for patients with relapsed/refractory hematologic malignancies. Despite encouraging efficacy, a subset of patients have poor clinical outcomes. We show that a simple clinically applicable model using pre-lymphodepletion CRP and ferritin can identify patients at high risk of poor outcomes. This article is featured in Selected Articles from This Issue, p. 80

Year:

2024

Year:

2022

Collaborators (18)

Sung-Gyoo Park

Seoul National University

SOUTH KOREA
View details

Xuefeng Wang

Associate Member/Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Je Kyung Seong

Assistant Professor, Associate Professor, Professor

Seoul National University

SOUTH KOREA
View details

Johannes Fahrmann

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marco Davila

SVP, Translational Research

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Jianmin Wang

Associate Professor

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Julio Chavez

Associate Professor

Moffitt Cancer Center

UNITED STATES
View details

Christina Bachmeier

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Hiroshi Kotani

Professor and Cairman

University of the Ryukyus

JAPAN
View details

Samir M. Hanash

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marion Subklewe

Head of Hematology with Focus on Cellular Therapy, CAR T and ECTU & LMU - Gene Center - Head of the Laboratory of Translational Cancer Immunology

Ludwig-Maximilians-Universität München

GERMANY
View details

Muhammad Junaid Tariq

Clinical Assisstant Professor

University of Florida

UNITED STATES
View details

Sankar Ghosh

Professor & Chairman

Columbia University Vagelos College of Physicians and Surgeons

UNITED STATES
View details

Timothy Shaw

Assistant Member/Professor

Moffitt Cancer Center

UNITED STATES
View details

Michael Jain

Associate Member

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details

Neeraj Y Saini

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Marion Subklewe

LMU University Hospital

GERMANY
View details

Paulo Rodriguez

Senior Member-Professor

H Lee Moffitt Cancer Center and Research Institute

UNITED STATES
View details